Year-end Sale % OFF 
Abstract
Since its discovery by von Euler 60 years ago, substance P has exercised the minds of pharmacologists and become of great interest for drug discovery. Because the peptide is a transmitter in pain endings in the spinal cord, pharmaceutical companies searching for novel analgesics have tried to synthesise specific and selective antagonists for the substance-P receptor, also known as the neurokinin 1 (NK1) receptor. Since the first report on such a compound in 19911 several substance-P antagonists have been synthesised, but none has been effective in reducing pain.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
